UnknownNot Applicable

The Impact of Oligo-Fucoidan in Cancer Cachexia and Sarcopenia

Taiwan100 participantsStarted 2022-01-30

Plain-language summary

Fucoidan also ameliorates tumour and chemotherapy-induced muscle atrophy and -related cachectic symptoms in vivo and in vitro. To evaluate the effect of fucoidan in cancer cachexia or sarcopenia in cancer patients.

Who can participate

Age range20 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Histologically confirmed patients with stage III-IV non-small cell lung cancer, colorectal carcinoma, head and neck cancer, nasopharyngeal cancer, or pancreatic carcinoma, who are not eligible for surgery, and interventional treatment .
✓. Chemotherapy regimen include platinum-based drugs and Gemcitabine based drugs;
✓. For patients who are being treated with chemotherapy, the chemotherapy regimen should be confined to the regimens specified in the protocol; and the chemotherapy regimen, in general, are not allowed to be changed during the study period;
✓. Patients are conscious and able to cooperate with the doctor to complete the disease-related examinations and evaluations;
✓. ECOG performance status (PS) 0-3 for those who are not treated with chemotherapy; and ECOG PS 0-2 for those who are being treated with chemotherapy;
✓. Expected survival period is more than 3 months;
✓. Male or female aged 20 - 90 years;
✓. Patients who are willing to participate in the study and sign the informed consent form.

Exclusion criteria

✕. Patients who are being treated with chemotherapy, the chemotherapy regimen is not among the regimens specified in the protocol;
✕. Patients with cachexia caused by other reasons, e.g. severe hepatic dysfunction \[Aspartate transaminase(AST)/Cerealthirdtransaminase(ALT) \>5 times the ULN\], severe renal dysfunction (Cr \>1.5 times the ULN), uncontrolled thyroid disease, New York Heart Association (NYHA) class III-IV heart failure, AIDS etc.;
✕. Any condition that may hinder the subject's completion of the study, including but not limited to severe uncontrollable organic diseases or infection, unstable angina pectoris, congestive heart failure, etc.;
✕. Known or suspected diagnosis of metastatic encephaloma;
✕. Patients present with an ECOG score\>2 and require treatment of chemotherapy;
✕. Patients who are currently included in other clinical trials on antineoplastic drugs;
✕. Patients who are not able to provide the Informed Consent Form (ICF);
✕. Expected survival period is less than 4 months;

What they're measuring

Body Weight

Timeframe: 0 day, 60th day, and 90th day Body weight change

Trial details

NCT IDNCT05623852

SponsorTaipei Medical University WanFang Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-04-30

Contact for this trial

Szu-Yuan Wu

+886910603955 szuyuanwu5399@gmail.com

View on ClinicalTrials.gov More Cachexia trials